Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhus coriaria ethanolic extract (RCE) is a botanical extract derived from the fruit of the *Rhus coriaria* plant, commonly known as sumac. It is primarily investigated for its potent anti-cancer and chemo-sensitizing properties. Research indicates that RCE exerts its effects by inducing apoptosis and modulating autophagy in various cancer types, including colorectal, pancreatic, and triple-negative breast cancers. A key mechanism involves the downregulation of Survivin (BIRC5), a member of the inhibitor of apoptosis (IAP) family, which helps overcome resistance to conventional chemotherapeutic agents like 5-fluorouracil (5-FU). The extract contains a complex mixture of phytochemicals, including tannins, flavonoids, and organic acids, which contribute to its antioxidant and anti-inflammatory activities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhus coriaria ethanolic extract.